Patent ID: 8613949

Claim:
A pharmaceutical oral fixed dose combination in the form of a monolayer tablet, comprising a) a therapeutically effective amount ranging from 10 to 45% by weight based on the total weight of the pharmaceutical oral fixed dose combination of aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount ranging from 0.5 to 5% of amlodipine, or a pharmaceutically acceptable salt thereof, c) a disintegrant in an amount of 2 to 15% by weight of the tablet, d) a diluent in an amount of 1 to 60% by weight, e) a binder in an amount of 0.1 to 20% by weight, f) a lubricant in an amount of 0.1 to 5% by weight, and g) a glidant in an amount of 0.5 to 5% by weight; wherein in each case not mentioned otherwise the percentage of weight being defined prior to any optional film coating, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component (a) of 60% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component (b) of 50% or more after 20 minutes, and 70% or more after 30 minutes at pH 2.